Maretti C, Cavallini G
Department of Andrology, Centro Medico Cirm (affiliated with GynePro), Outpatient Clinic of Piacenza, Piacenza, Italy.
Department of Andrology, GynePro Medical Group, Bologna, Italy.
Andrology. 2017 May;5(3):439-444. doi: 10.1111/andr.12336. Epub 2017 Feb 28.
The hypothesis that the assumption of a probiotic associated with a prebiotic (Flortec, Bracco; one sachet contains: Lactobacillus paracasei B21060 5 × 10 cells + arabinogalctan 1243 mg + oligo-fructosaccharides 700 mg + l-glutamine 500 mg) could improve the quality and quantity of spermatozoa in idiopathic oligoasthenoteratospermia (iAOT) patients to a larger extent than a control substance (starch) was tested. Forty-one patients with no chromosomal aberrations were randomized into two groups: 20 received Flortec, one sachet per day for 6 months, whereas 21 received the control substance. The following data were collected: clinical history, scrotal Doppler scans, Y microdeletion, karyotype and cystic fibrosis screens, follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), testosterone (T), and prolactin (PRL) levels, and two semen analyses. Both the Flortec and the starch groups underwent two semen analyses and one FSH, LH, T, E2, and PRL measurement in the blood, at the beginning of the study, and after 6 months. The comparisons were carried out using a non-parametric (Wilcoxon signed rank) test. The side effects were assessed and compared using the chi-squared test. Group 1 (Flortec) had their sperm count improved: volume of the ejaculate (median from 2.4 to 3.1 mL; p < 0.01), sperm concentration (median: from 15.2 × 10 /mL to 28.3 × 10 /39 mL; p < 0.01), progressive motility (median: from 16.2 to 42.0%; p < 0.01), and the percentage of typical forms (median: from 7 to 16.3%; p < 0.01); in addition, their FSH, LH, and T levels improved (p < 0.01), while those of E2 and PRL did not. Group 2 (control substance) had no modification in 42 of the parameters studied. There were no side effects in either group. These data showed that Flortec constitutes a safe therapy for improving the volume of the ejaculate and the quality/quantity of spermatozoa in iOAT patients.
一项关于益生菌与益生元组合制剂（弗洛泰克，布拉科公司生产；每袋含有：副干酪乳杆菌B21060 5×10个细胞 + 阿拉伯半乳聚糖1243毫克 + 低聚果糖700毫克 + L - 谷氨酰胺500毫克）能否比对照物质（淀粉）更大程度改善特发性少弱畸精子症（iAOT）患者精子质量和数量的假说得到了验证。41名无染色体畸变的患者被随机分为两组：20名患者接受弗洛泰克治疗，每天一袋，持续6个月，而另外21名患者接受对照物质治疗。收集了以下数据：临床病史、阴囊多普勒扫描、Y染色体微缺失、核型和囊性纤维化筛查、促卵泡激素（FSH）、促黄体生成素（LH）、雌二醇（E2）、睾酮（T）和催乳素（PRL）水平，以及两次精液分析。在研究开始时和6个月后，弗洛泰克组和淀粉组均进行了两次精液分析以及一次血液中FSH、LH、T、E2和PRL的测量。比较采用非参数（威尔科克森符号秩）检验。使用卡方检验评估和比较副作用。第1组（弗洛泰克组）的精子计数得到改善：射精量（中位数从2.4毫升增至3.1毫升；p < 0.01）、精子浓度（中位数：从15.2×10⁶/毫升增至28.3×10⁶/39毫升；p < 0.01）、前向运动能力（中位数：从16.2%增至42.0%；p < 0.01）以及正常形态精子百分比（中位数：从7%增至16.3%；p < 0.01）；此外，他们的FSH、LH和T水平也有所改善（p < 0.01），而E2和PRL水平未变。第2组（对照物质组）所研究的42项参数均无变化。两组均未出现副作用。这些数据表明，弗洛泰克是一种安全的治疗方法，可改善iOAT患者的射精量以及精子的质量/数量。
